I am a breastfeeding mother and i want to know if it is safe to use Benznidazolum [INN-Latin]? Is Benznidazolum [INN-Latin] safe for nursing mother and child? Does Benznidazolum [INN-Latin] extracts into breast milk? Does Benznidazolum [INN-Latin] has any long term or short term side effects on infants? Can Benznidazolum [INN-Latin] influence milk supply or can Benznidazolum [INN-Latin] decrease milk supply in lactating mothers?
- DrLact safety Score for Benznidazolum [INN-Latin] is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of Benznidazolum [INN-Latin] is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that Benznidazolum [INN-Latin] does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of Benznidazolum [INN-Latin] safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Antiprotozoan drug used for the treatment of American Trypanosomiasis (Trypanosoma cruzi) or Chagas Disease (see specific info). It is excreted into breast milk in small amounts and there have not been observed problems in infants from treated mothers (Garcia-Bournissen 2015, Vela-Bahena 2015). Benznidazolum [INN-Latin] has been very well tolerated when administered directly to infants and newborns (Altcheh 2011, Chippaux 2013).
Benznidazolum [INN-Latin] is excreted into milk in dosages much lower than the treatment dosage for infants. Because of the low levels of Benznidazolum [INN-Latin] in breastmilk and safety when given directly to infants, its use is acceptable in nursing mothers.
Ten women with chronic Chagas disease received Benznidazolum [INN-Latin] in a median oral dose of 5.65 mg/kg twice daily for 30 days. Median infant age Ten women with chronic Chagas disease received Benznidazolum [INN-Latin] in a median oral dose of 5.65 mg/kg twice daily for 30 days. Median infant age was 5.2 months (range 20 days-13 months). Five children were exclusively breastfed and the others partially breastfed. None of the infants had any adverse reactions attributable to Benznidazolum [INN-Latin].[4] A postpartum woman diagnosed with Chagas disease was treated with Benznidazolum [INN-Latin] 5 mg/kg daily beginning one month postpartum and continuing for 30 days. She continued to breastfeed (extent not stated) her infant. The authors reported that no adverse effects were seen in the infant.[6]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.